Alteogen Biologics Licenses Papilocare HPV Device for Korea
The Korean biotech firm secured rights from Spain's Procare Health today for an intravaginal gel device to manage human papillomavirus (HPV) infection and cervical lesions.
Alteogen Biologics Secures Korean Rights
Alteogen Biologics, a subsidiary of Korean biotech company Alteogen, announced today it has finalized a licensing agreement for Papilocare, an intravaginal medical device. The deal grants Alteogen Biologics exclusive rights to distribute and market the device in Korea.
Papilocare, developed by Spanish women's health firm Procare Health, is designed for the management of human papillomavirus (HPV) infection and associated cervical lesions. This strategic move aims to expand Alteogen Biologics' presence in the women's health sector within the Korean market.
Clinical Evidence for Papilocare
Papilocare functions as a gel-form device, intended to support the recovery and normalization of HPV-associated cervical lesions by encouraging the re-epithelialization of the cervical and vaginal mucosa. The company stated that clinical evidence for Papilocare comes from two randomized controlled trials conducted in Europe, known as PALOMA 1 and PALOMA 2.
A combined analysis of these trials showed an 85.4 percent high-risk HPV clearance rate in the Papilocare group at six months, compared to 43.4 percent in the control group. Furthermore, in the PALOMA 2 study, the normalization rate for high-risk HPV-positive low-grade cervical lesions reached 84.6 percent in the treatment group, against 46.4 percent in control subjects.
Expanding Women's Health Portfolio
Papilocare is currently available in over 65 countries globally, according to Procare Health. For Alteogen Biologics, this licensing agreement marks a significant expansion of its obstetrics and gynaecology business. The Korean firm already handles the distribution and marketing of LG Chem's anti-adhesion agent, Protescal, in Korea.
By adding Papilocare to its portfolio, Alteogen Biologics is moving into the specialized area of HPV and cervical health management, diversifying its offerings within the medical device and women's health segments.
Korean Market Implications for HPV Management
The introduction of Papilocare into the Korean market by Alteogen Biologics addresses a specific need in women's health. Persistent high-risk HPV infection can lead to cervical dysplasia and potentially cervical cancer, and currently no approved drug directly eliminates the infection.
Management often relies on repeat testing and observation for HPV-positive cases and low-grade cervical lesions. This licensing deal provides a new option for medical professionals in Korea, potentially offering an adjunctive treatment to support recovery and normalization for patients managing HPV infections and related lesions. Korean clinics and gynaecology practices can now consider integrating Papilocare into their patient care protocols.
Three newsletters, one newsroom.
The Beauty Brief delivers Asia's beauty week every Monday. Regulatory Radar tracks the rule changes that move markets. Trend Pulse decodes what consumers want next. All free to start.
